Is tau upside-down 18F-FDG? van Eimeren and colleagues highlight areas in which tau imaging may offer additional clinical value to that of 18F-FDG PET in elucidating mechanisms of neurodegeneration.
Page 1357
Pediatric PET/CT: Fahey and colleagues offer an educational overview of factors that affect CT radiation dose, ways that CT is used in the context of PET/CT, and approaches to integrating PET/CT and diagnostic CT in children.
Page 1360
Optical imaging of human organoids: Walsh and colleagues describe primary tumor organoids as a model for use in cancer research and as a platform for drug screening with optical metabolic imaging, which can probe organoid cells for drug-resistant subpopulations.
Page 1367
64Cu-DOTA-alendronate breast imaging: Ahrens and colleagues evaluate this tracer as a microcalcification-targeting PET imaging agent in a rat model, with a long-term goal of differentiating malignant from benign lesions.
Page 1373
Brachytherapy with 90Y-polyoxazoline: Sano and colleagues report on brachytherapy using biocompatible, injectable thermoresponsive polymers that can self-aggregate above a specific transition temperature, resulting in long-term intratumoral retention of radioactivity.
Page 1380
89Zr-DFO-AMG102 for HGF: Price and colleagues detail synthesis, radiolabeling, and in vitro and in vivo validation of this new immuno-PET imaging agent, which accumulates selectively in tumors with high local levels of hepatocyte growth factor protein.
Page 1386
Cerenkov radiation–induced PIT: Nakamura and colleagues demonstrate the feasibility of using Cerenkov radiation generated by 18F-FDG accumulated in tumors to induce photoimmunotherapy.
Page 1395
GRPR expression in breast cancer: Morgat and colleagues screen a large number of invasive breast cancers with immunohistochemistry for the presence and intensity of gastrin-releasing peptide receptor expression, a potentially valuable treatment target.
Page 1401
99mTc-trofolastat SPECT/CT in PCa: Goffin and colleagues assess the SPECT performance of this small-molecule inhibitor of prostate-specific membrane antigen in patients with intermediate- and high-grade prostate cancer before radical prostatectomy and pelvic lymph node dissection.
Page 1408
PET after anal cancer treatment: Houard and colleagues report on the relevance of 18F-FDG PET/CT as a strategy for response evaluation, including predictive value, after chemoradiation for anal cancer.
Page 1414
PET/CT and immune checkpoint blockade: Cho and colleagues describe the utility of 18F-FDG PET/CT imaging as an early predictor of response to immune checkpoint inhibitors in patients with advanced melanoma.
Page 1421
Variability of response measurement: O and colleagues look at interobserver variability in quantitative 18F-FDG PET/CT parameters used in assessments of oncologic treatment response across multiple sites and readers.
Page 1429
SSTR antagonists: Nicolas and colleagues investigate the biodistribution, pharmacokinetics, SPECT/CT characteristics, and dosimetry of a somatostatin receptor 2 antagonist labeled with 177Lu, 90Y, and 111In and compare these with 177Lu-DOTATATE.
Page 1435
PSMA therapeutics: Kelly and colleagues report on new dual-target small molecules with high-affinity targeting to prostate cancer cells through interaction with prostate-specific membrane antigen and moderate affinities for albumin, with potential for use in targeted α-therapy.
Page 1442
Perspective on 68Ga-DOTATOC imaging: Mailman provides retrospective highlights and a patient’s viewpoint on development of PET/CT imaging in neuroendocrine tumor therapy and introduces an article on this topic in this issue of JNM.
Page 1450
68Ga-DOTATOC imaging: Graham and colleagues report on the results of a systematic review and meta-analysis of the efficacy of this somatostatin receptor–targeted ligand for several distinct indications, with data in support of U.S. FDA approval.
Page 1452
Predictive CZT SPECT: Engbers and colleagues determine the prognostic value of myocardial perfusion imaging with a cadmium-zinc-telluride SPECT camera in a large cohort of patients with suspected coronary artery disease.
Page 1459
Initial evaluation of 11C-preladenant: Sakata and colleagues describe first-in-human studies of safety, radiation dosimetry, and imaging with this selective antagonist for mapping of cerebral adenosine A2A receptors with PET.
Page 1464
Impaired CSF clearance in AD: de Leon and colleagues use dynamic PET with 18F‐THK5117, a tracer for tau pathology, to estimate ventricular cerebrospinal fluid time–activity as a biomarker for CSF clearance in Alzheimer disease.
Page 1471
TSPO PET in MS: Datta and colleagues use PET with translocator protein radioligands to assess microglial activation in lesions and in normal-appearing white matter in patients with multiple sclerosis.
Page 1477
AV45 kinetic modeling vs. static imaging: Ottoy and colleagues compare the SUV ratio method for 18F-AV45 uptake quantitation on PET with the gold standard volume of distribution to assess differences in plaque load in elderly patients.
Page 1483
PET and anticonvulsant-induced cognitive impairment: Zhu and colleagues explore correlations between monoamine receptor PET imaging and additional imaging and clinical assessments in patients after anticonvulsant therapies, emphasizing the role of monoamine receptor dysfunction in anticonvulsant-induced cognitive impairment.
Page 1490
18F-THK-5351 radiation dosimetry: Hsiao and colleagues estimate in humans the radiation dose of this novel radiotracer with high binding selectivity for tau and compare clinical radiation dosimetry results with previous preclinical data.
Page 1498
PET/CT in S. aureus bacteremia: Berrevoets and colleagues investigate the utility of 18F-FDG PET/CT in patients with Staphylococcus aureus bacteremia, with a focus on detection of metastatic infection and consequences for treatment and outcome.
Page 1504
Next-generation PET/CT system: Hsu and colleagues detail system performance studies for the Discovery MI PET/CT system, a new time-of-flight system based on silicon photomultipliers.
Page 1511
PET/MR for oncologic brain imaging: Rausch and colleagues compare standard MR-based attenuation correction for PET/MR imaging with a model-based approach for the Siemens mMR PET/MR system.
Page 1519
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.